참고문헌
- Berne R, Levy M. Skeletal physiology. In: Berne R, Levy M, eds. Physiology. St. Louis: Mosby Yearbook, 1993:292-308
- Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80 https://doi.org/10.1007/BF01081524
- Webster L. Drugs used in chemotherapy of protozoal infections. In: Gilman A, Rail T, Nies A, Taylor P, eds. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990:1002-4
- Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981;43:546-50 https://doi.org/10.1038/bjc.1981.79
- Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med 1999;29:330-8 https://doi.org/10.1016/S0001-2998(99)80020-8
- Franko AJ. Misonidazole and other hypoxia markers: Metabolism and applications. Int J Radiat Oncol Biol Phys 1986;12:1195-202 https://doi.org/10.1016/0360-3016(86)90257-9
- Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 1987;28:68-75
-
Jette DC, Wiebe LI, Chapman JD. Synthesis and in vivo studies of the radiosensitizer
$4-[^{82}br]$ bromomisonidazole. Int J Nucl Med Biol 1983;10:205-10 https://doi.org/10.1016/0047-0740(83)90080-3 -
Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of
$^{18}F$ -labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum [A] 1986;37:599-605 https://doi.org/10.1016/0883-2889(86)90079-1 - Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-50
- Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304 https://doi.org/10.2307/3576986
- Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91 https://doi.org/10.1016/0360-3016(89)90146-6
- Martin GV, Cerqueira MD, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res 1990;67:240-4 https://doi.org/10.1161/01.RES.67.1.240
- Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium. J Nucl Med 1989;30:351-8
-
Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueira M, Krohn KA. Enhanced binding of the hypoxic cell marker
$[^3H]$ fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201 - Shelton ME, Dence CS, Hwang DR, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: A potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990;16:477-85 https://doi.org/10.1016/0735-1097(90)90606-P
- Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 1995;36:1633-8
- Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 1995;2:437-45 https://doi.org/10.1016/S1071-3581(05)80031-5
- Linder KE, Chan YW, Cyr JE, Nowotnik DP, Eckelman WC, Nunn AD. Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: New technetium compounds designed for imaging hypoxic tissue. Bioconjug Chem 1993;4: 326-33 https://doi.org/10.1021/bc00023a004
- Ng CK, Sinusas AJ, Zaret BL, Soufer R. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. Circulation 1995;92:1261-8 https://doi.org/10.1161/01.CIR.92.5.1261
-
Stone CK, Mulnix T, Nickles RJ, Renstrom B, Nellis SH, Liedtke AJ, et al. Myocardial kinetics of a putative hypoxic tissue marker,
$^{99m}Tc$ -labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. Circulation 1995;92:1246-53 https://doi.org/10.1161/01.CIR.92.5.1246 - Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, et al. Technetium-99m-nitroimidazole (BMS181321): A positive imaging agent for detecting myocardial ischemia. J Nucl Med 1995;36:1078-86
- Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17 https://doi.org/10.1021/jm00027a002
- Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023-31
- Johnson LL, Schofield L, Mastrofrancesco P, Donahay T, Nott L. Technetium-99m-nitroimadazole uptake in a swine model of demand ischemia. J Nucl Med 1998;39:1468-75
-
Okada RD, Johnson G, 3rd, Nguyen KN, Liu Z, Edwards B, Archer CM, et al.
$^{99m}Tc$ -HL91: 'hot spot' detection of ischemic myocardium in vivo by gamma camera imaging. Circulation 1998;97:2557-66 https://doi.org/10.1161/01.CIR.97.25.2557 -
Johnson LL, Schofield L, Donahay T, Mastrofrancesco P. Myocardial uptake of a
$^{99m}Tc$ -nitroheterocycle in a swine model of occlusion and reperfusion. J Nucl Med 2000;41:1237-43 - Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60